View text source at Wikipedia

Lanifibranor

Lanifibranor
Identifiers
  • 4-[1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
ECHA InfoCard100.218.645 Edit this at Wikidata
Chemical and physical data
FormulaC19H15ClN2O4S2
Molar mass434.91 g·mol−1
3D model (JSmol)
  • C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2
  • InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)
  • Key:OQDQIFQRNZIEEJ-UHFFFAOYSA-N

Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) receptor agonist and is the first medication that targets PPAR-alpha, PPAR-beta, and PPAR-gamma simultaneously.[1][2][3] As of 2023, it is in a phase III trial for nonalcoholic steatohepatitis; its advantage over other drugs that are in phase III trials for the same condition is that it has shown improvements in both steatohepatitis and fibrosis.[4]

References

[edit]
  1. ^ Derrett-Smith, Emma; Clark, Kristina E. N.; Shiwen, Xu; Abraham, David J.; Hoyles, Rachel K.; Lacombe, Olivier; Broqua, Pierre; Junien, Jean Louis; Konstantinova, Irena; Ong, Voon H.; Denton, Christopher P. (6 September 2021). "The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis". Arthritis Research & Therapy. 23 (1): 234. doi:10.1186/s13075-021-02592-x. ISSN 1478-6362. PMC 8419933. PMID 34488870.
  2. ^ Boyer-Diaz, Zoe; Aristu-Zabalza, Peio; Andrés-Rozas, María; Robert, Claude; Ortega-Ribera, Martí; Fernández-Iglesias, Anabel; Broqua, Pierre; Junien, Jean-Louis; Wettstein, Guillaume; Bosch, Jaime; Gracia-Sancho, Jordi (May 2021). "Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease". Journal of Hepatology. 74 (5): 1188–1199. doi:10.1016/j.jhep.2020.11.045. PMID 33278455.
  3. ^ Francque, Sven M.; Bedossa, Pierre; Ratziu, Vlad; Anstee, Quentin M.; Bugianesi, Elisabetta; Sanyal, Arun J.; Loomba, Rohit; Harrison, Stephen A.; Balabanska, Rozalina; Mateva, Lyudmila; Lanthier, Nicolas; Alkhouri, Naim; Moreno, Christophe; Schattenberg, Jörn M.; Stefanova-Petrova, Diana; Vonghia, Luisa; Rouzier, Régine; Guillaume, Maeva; Hodge, Alexander; Romero-Gómez, Manuel; Huot-Marchand, Philippe; Baudin, Martine; Richard, Marie-Paule; Abitbol, Jean-Louis; Broqua, Pierre; Junien, Jean-Louis; Abdelmalek, Manal F. (21 October 2021). "A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH". New England Journal of Medicine. 385 (17): 1547–1558. doi:10.1056/NEJMoa2036205. hdl:10067/1822390151162165141. ISSN 0028-4793. PMID 34670042.
  4. ^ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). "Clinical Trial Landscape in NASH". Clinical Gastroenterology and Hepatology. 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041. PMID 37059159. S2CID 258115543.